Oncolytics Biotech Inc
TSX:ONC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hebei Sailhero Environmental Protection High-tech Co Ltd
SZSE:300137
|
CN |
Oncolytics Biotech Inc
Total Receivables
Oncolytics Biotech Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oncolytics Biotech Inc
TSX:ONC
|
Total Receivables
CA$72k
|
CAGR 3-Years
-42%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Receivables
CA$413.1k
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Receivables
$41.5m
|
CAGR 3-Years
45%
|
CAGR 5-Years
111%
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Receivables
$1.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
16%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Receivables
CA$674.2k
|
CAGR 3-Years
78%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Receivables
$927k
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Oncolytics Biotech Inc
Glance View
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 26 full-time employees. The company went IPO on 2000-06-01. The firm is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.
See Also
What is Oncolytics Biotech Inc's Total Receivables?
Total Receivables
72k
CAD
Based on the financial report for Jun 30, 2025, Oncolytics Biotech Inc's Total Receivables amounts to 72k CAD.
What is Oncolytics Biotech Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
2%
Over the last year, the Total Receivables growth was -95%. The average annual Total Receivables growth rates for Oncolytics Biotech Inc have been -42% over the past three years , 4% over the past five years , and 2% over the past ten years .
